Categories: SCHD24

Binaytara Foundation Announces 2024 Career Advancement Award Recipients

This week, the Binaytara Foundation (BTF) is proud to announce its 2024 Career Advancement Award recipients: Dr. Emmanuella Oyogoa (Oregon Health & Science University), Dr. Kelly Jasmin Meza-Capcha (Baylor College of Medicine), Dr. Ayo S. Falade (Mass General Brigham Salem), Dr. Álvaro Menéndez (Hartford HealthCare), and Dr. Cynthia Eleanya (National Institutes of Health). On April 26-28, the recipients will attend the annual Summit on Cancer Health Disparities (SCHD24) in Seattle, WA. The Summit will grant the awardees the opportunity to network with prominent leaders in the field of oncology through our Career Connections Workshop.

 

The award winners, all in early stages of their medical careers, have already begun working to alleviate healthcare disparities, and BTF wishes to shine a light on the potential that they show in their respective fields. Dr. Cynthia Eleanya wrote her abstract on “elucidating the barriers to Hematopoietic Stem Cell transplant for patients with Hematologic Malignancies at the National Institutes of Health (NIH).” She wrote her abstract in an effort to begin her work on reducing disparities in cancer outcomes through both clinical research and patient care. 

 

When asked what inspires him to pursue equity in health care, award winner Dr. Ayo S. Falade said: “premature cancer death and unrealized potential stem from entrenched inequities based in socioeconomic status and geography. This status quo is unacceptable.” The Binaytara Career Advancement Award program’s ultimate aim is to connect underrepresented in medicine (URiM) hematology-oncology trainees and early-career physicians with some of the leading experts in cancer care. In this way, BTF hopes to improve mentorship and encourage collaboration between new and expert medical professionals, particularly those early-career physicians who have themselves seen and struggled with healthcare inequity. 

 

Award recipient Dr. Alvaro Menendez commented on the impact of the Summit, saying: “The opportunities for career advancement provided by the Binaytara Foundation potentiate our efforts to minimize healthcare disparities that exist in cancer care by providing mentoring opportunities from world experts.” Through such initiatives, BTF plays a pivotal role in nurturing the next generation of medical professionals and researchers. The impact of this program is expected to resonate far beyond SCHD24, as the recipients bring back valuable insights and connections to their respective institutions and communities to help continue advancing equity in healthcare.

Elaina Harris

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

5 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

5 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago